Rheumatiod arthritis: Preventative treatment

Rheumatoid arthritis (sometimes called “RA”) is a common chronic inflammatory disease that affects around 1% of the population. It is 2-3 times more common in women. In most cases, patients begin having symptoms between 40 to 60 years of age, but it can begin earlier, or later in life.

RA affects the joints and causes pain, swelling, and stiffness, but also fatigue. If patients are not treated, the joints can suffer permanent damage, which subsequently can lead to disability. To date, there is no cure, which means that for the vast majority of patients treatments are long term, with the aim of controlling the inflammatory disease activity and reducing symptoms.

There is increasing research interest in the idea of treating individuals who are at an increased risk of developing RA to assess whether a relatively short course of therapy will prevent or delay the onset of RA. One such ‘at risk’ group are the siblings and children of patients with RA, who are four times more likely to develop the disease. The presence of RA-related autoantibodies in the blood increases the risk of developing the disease further.

This PREFER case study will ask siblings, children and members of the general public about their preferences for preventive treatments for RA. The case study will further look at how participant characteristics, country (UK vs Germany), population (siblings and children vs. general population), knowledge/experience with RA will impact on these treatment preferences. In addition, this case study will evaluate the similarity of two different methods to measure treatment preferences.

Fact sheet

Therapeutic area Rheumatoid arthritis
Study led by University of Birmingham

University of Erlangen
PREFER leads team Karim Raza
Marie Falahee
Larissa Vaylor-Mendez

Jorien Veldwijk
Rachael DiSantostefano
MPLC decision points of interest Early-development and post-marketing
PREFER case study acronym RA
Clinical objectives Assessing the preferences of people at risk of RA for preventive treatments

Evaluating the maximum acceptable risk (MAR)/Minimum acceptable benefit (MAB)

Characterising preference heterogeneity and characteristics that may explain heterogeneity
Patients from United Kingdom
Germany
Methods in Qualitative study Focus group discussion
Nominal group technique
Methods in Quantitative study DCE 
Probabilistic Threshold Technique
End-date qualitative data collection December 2019
End-date quantitative data collection Q3 2020